hENT1 Expression Predicts Response to Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Ductal Adenocarcinoma
Authors:
- Sheron PereraSPSheron Perera
- Gun Ho JangGJGun Ho Jang
- Yifan WangYWYifan Wang
- Deirdre KellyDKDeirdre Kelly
- Michael AllenMAMichael Allen
- Amy ZhangAZAmy Zhang
- Robert E. DenrocheRDRobert E. Denroche
- Anna DoddADAnna Dodd
- Stephanie RamotarSRStephanie Ramotar
- Shawn HutchinsonSHShawn Hutchinson
- Mustapha TehfeMTMustapha Tehfe
- Ravi RamjeesinghRRRavi Ramjeesingh
- 12 October 2022
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 28 (23) , 5115-5120
Abstract
Purpose: Modified FOLFIRINOX (mFFX) and gemcitabine/nab-paclitaxel (GnP) remain standard first-line options for patients with advanced pancreatic ductal adenocarcinoma (PDAC). Human equilibrative nucleoside transporter 1 (hENT1) was hypothesized to be a biomarker of gemcitabine in the adjuvant setting, with conflicting results. In this study, we explore hENT1 mRNA expression as a predictive biomarker in advanced PDAC. Experimental Design: COMPASS was a prospective observational trial of patients with advanced PDAC. A biopsy was required prior to initiating chemotherapy, as determined by treating physician. Biopsies underwent laser capture microdissection prior to whole genome and RNA sequencing. The cut-off thresholds for hENT1 expression were determined using the maximal χ2 statistic. Results: 253 patients were included in the analyses with a median follow-up of 32 months, with 138 patients receiving mFFX and 92 receiving GnP. In the intention to treat population, median overall survival (OS) was 10.0 months in hENT1high versus 7.9 months in hENT1low (P = 0.02). In patients receiving mFFX, there was no difference in overall response rate (ORR; 35% vs. 28%, P = 0.56) or median OS (10.6 vs. 10.5 months, P = 0.45). However, in patients treated with GnP, the ORR was significantly higher in hENT1high compared with hENT1low tumors (43% vs. 21%, P = 0.038). Median OS in this GnP-treated cohort was 10.6 months in hENT1high versus 6.7 months hENT1low (P < 0.001). In an interaction analysis, hENT1 was predictive of treatment response to GnP (interaction P = 0.002). Conclusions: In advanced PDAC, hENT1 mRNA expression predicts ORR and OS in patients receiving GnP.Keywords
All Related Versions
Funding Information
- Terry Fox Research Institute (TFRI 1078)
- Ontario Institute for Cancer Research (I.PANC 399985)
- QEII Foundation
- Craig's Cause Pancreatic Cancer Society
- Canadian Cancer Society Research Institute (702316)
- Ministère des Services à l'enfance et des Services sociaux et communautaires, Gouvernement de l'Ontario
- Princess Margaret Cancer Foundation
- Pancreatic Cancer Canada Foundation
- Wallace McCain Centre for Pancreatic Cancer
This publication has 22 references indexed in Scilit:
- Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal AdenocarcinomaJAMA Oncology, 2017
- HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signaturesNature Medicine, 2017
- Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinomaNature Genetics, 2015
- Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 TrialJNCI: Journal of the National Cancer Institute, 2013
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus GemcitabineNew England Journal of Medicine, 2013
- STAR: ultrafast universal RNA-seq alignerBioinformatics, 2012
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiationNature Biotechnology, 2010
- Transcription Analysis of Human Equilibrative Nucleoside Transporter-1 Predicts Survival in Pancreas Cancer Patients Treated with GemcitabineCancer Research, 2006
- The Absence of Human Equilibrative Nucleoside Transporter 1 Is Associated with Reduced Survival in Patients With Gemcitabine-Treated Pancreas AdenocarcinomaClinical Cancer Research, 2004